Comparative Gastrointestinal Bleeding Risk of Clopidogrel versus Aspirin

Evidence from Head‑to‑Head Trials

In the CAPRIE trial (large randomized controlled trial of >19,000 patients), gastrointestinal hemorrhage occurred in 2.0 % of patients receiving clopidogrel compared with 2.7 % of those receiving aspirin (absolute difference ≈0.7 %). Bleeding requiring hospitalization was 0.7 % with clopidogrel versus 1.1 % with aspirin【1】.
The same trial showed that dual antiplatelet therapy (aspirin + clopidogrel) increased GI bleeding risk 2–3‑fold relative to aspirin alone, with an absolute risk increase ranging from 0.6 % to 2.0 %【1】【4】.

Aspirin is directly ulcerogenic: it causes local mucosal injury and systemic prostaglandin depletion, leading to ulcer formation【3】.
Clopidogrel does not cause ulcers or erosions; it can exacerbate bleeding from pre‑existing lesions through its antiplatelet effect【1】【4】.

In patients with a history of peptic ulcer disease or prior GI bleeding, the safety advantage of clopidogrel disappears or reverses【5】.
Two randomized trials demonstrated that low‑dose aspirin (75–100 mg) combined with a proton‑pump inhibitor (esomeprazole) is superior to clopidogrel monotherapy for preventing recurrent GI bleeding in this population【5】.
Consequently, clopidogrel should not be assumed safer in high‑risk patients; the preferred strategy is low‑dose aspirin plus PPI【5】.

Aspirin 75–100 mg/day produces less GI bleeding than 300–325 mg/day【6】【7】.
No dose‑response relationship exists for antiplatelet efficacy, supporting the use of the lowest effective dose【6】【7】.
Enteric‑coated or buffered aspirin formulations do not reduce major upper GI bleeding risk compared with plain tablets【5】.

History of peptic ulcer disease or prior GI bleeding (strongest predictor)【1】.
Concurrent use of anticoagulants, NSAIDs, or systemic corticosteroids【1】.
Helicobacter pylori infection【1】.

Average‑risk patients: clopidogrel offers a modestly lower GI bleeding risk (≈0.7 % absolute difference per year) compared with aspirin【1】.
High‑risk patients (prior ulcer/GI bleed): low‑dose aspirin (75–100 mg) plus a proton‑pump inhibitor is preferred over clopidogrel monotherapy【5】.

Do not switch to clopidogrel in patients with recent aspirin‑associated ulcer bleeding without first considering aspirin + PPI, which yields better outcomes【5】.
Do not assume that enteric‑coated aspirin reduces GI bleeding risk; evidence shows no benefit【5】.